fenofibrate and mbx-8025

fenofibrate has been researched along with mbx-8025 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y1
Bates, J; Breckenridge, DG; Hollenback, D; Kusam, S; Mahadevan, S; Marchand, B; Okesli-Armlovich, A; Olson, I; Seung, M; Toteva, M; Trevaskis, JL; Vijayakumar, A; Wang, T1

Reviews

1 review(s) available for fenofibrate and mbx-8025

ArticleYear
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
    Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10

    Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary

2020

Other Studies

1 other study(ies) available for fenofibrate and mbx-8025

ArticleYear
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Hepatology communications, 2022, Volume: 6, Issue:9

    Topics: Acetates; Acetyl-CoA Carboxylase; Animals; Fenofibrate; Humans; Hypertriglyceridemia; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; PPAR alpha; Rats; Triglycerides

2022